Nurix Therapeutics Enters $3 Billion Cancer Drug Deal with Roche
Nurix Therapeutics (NRIX) shares surged after announcing a global collaboration and licensing agreement worth up to $3 billion with Roche. The deal includes an upfront payment of $700 million for the development and commercialization of bexobrutideg, an oral BTK degrader.
Tickers: $NRIX
Topics: BTK Inhibitors Collaboration Agreements Pharmaceuticals